-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOAGE LABS ANNOUNCES FIRST PARTICIPANT DOSED IN QUELL-DME, A PHASE 2 TRIAL OF BGE-102, A NOVEL ORAL NLRP3 INHIBITOR, IN DIABETIC MACULAR EDEMA

Reuters·09/08/2026 12:00:00

Please log in to view news